Delay of surgery for melanoma among medicare beneficiaries

JAMA Dermatology

Volumn 151, Issue 7, 2015, Pages 731-741

  Lott, Jason P ^a,b   Narayan, Deepak ^a   Soulos, Pamela R ^a   Aminawung, Jenerius ^a   Gross, Cary P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CAUCASIAN; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MEDICARE; MELANOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO; SOCIAL STATUS; THERAPY DELAY; TUMOR BIOPSY; VERY ELDERLY; AGE; BIOPSY; CANCER REGISTRY; DERMATOLOGY; HEAD AND NECK NEOPLASMS; LIMB; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PLASTIC SURGERY; PRIMARY HEALTH CARE; RISK FACTOR; SECONDARY; SKIN; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT; TRUNK; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY; COMORBIDITY; DERMATOLOGY; EXTREMITIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEDICARE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; SKIN; SKIN NEOPLASMS; SURGERY, PLASTIC; TIME-TO-TREATMENT; TORSO; UNITED STATES;

EID: 84937604298     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.119     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Huff LS, Chang CA, Thomas JF, et al. Defining an acceptable period of time from melanoma biopsy to excision. Dermatol Reports. 2012;4(1):e2. doi:10.4081/dr.2012.e2.
3. McKenna DB, Lee RJ, Prescott RJ, Doherty VR. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. Br J Dermatol. 2002;147(1):48-54.
4. Riker AI, Glass F, Perez I, Cruse CW, Messina J, Sondak VK. Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther. 2005;18(5):387-393.
5. Plym A, Ullenhag GJ, Breivald M, Lambe M, Berglund A. Clinical characteristics, management and survival in young adults diagnosed with malignant melanoma: a population-based cohort study. Acta Oncol. 2014;53(5):688-696.
6. Carpenter S, Pockaj B, Dueck A, et al. Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome? Am J Surg. 2008;196(6):834-842.
7. Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253(4):779-785.
8. Bardell T, Belliveau P, Kong W, Mackillop WJ. Waiting times for cancer surgery in Ontario: 1984-2000. Clin Oncol (R Coll Radiol). 2006;18(5):401-409.
9. Spurgeon P, Barwell F, Kerr D. Waiting times for cancer patients in England after general practitioners' referrals: retrospective national survey. BMJ. 2000;320(7238):838-839.
10. Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. Thorax. 2009;64(9):749-756.
11. Korsgaard M, Pedersen L, Sørensen HT, Laurberg S. Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer. Cancer Detect Prev. 2006;30(4):341-346.
12. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review.Lancet. 1999;353(9159):1119-1126.
13. Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer. 1999;79(5-6):858-864.
14. McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol. 2012;30(36):4493-4500.
15. Fradet Y, Aprikian A, Dranitsaris G, Siemens R, Tsihlias J, Fleshner N; Canadian Surgical Wait Times (SWAT) Initiative. Does prolonging the time to bladder cancer surgery affect long-term cancer control? a systematic review of the literature. Can J Urol. 2006;13(suppl 3):37-47.
16. Bishop MC. The dangers of a long urological waiting list. BrJUrol.1990;65(5):433-440.
17. Epstein E, Bragg K, Linden G. Biopsy and prognosis of malignant melanoma. JAMA. 1969;208(8):1369-1371.
18. Snow SN, Mohs FE, Oriba HA, Dudley CM, Leverson G, Hetzer M. Cutaneous malignant melanoma treated by Mohs surgery: review of the treatment results of 179 cases from the Mohs Melanoma Registry. Dermatol Surg. 1997;23(11):1055-1060.
19. Chin-Lenn L, Murynka T, McKinnon JG, Arlette JP. Comparison of outcomes for malignant melanoma of the face treated using Mohs micrographic surgery and wide local excision. Dermatol Surg. 2013;39(11):1637-1645.
20. Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52(1):92-100.
21. National Cancer Institute. Surveillance, Epidemiology, and End Results Program fact sheet. http://appliedresearch.cancer.gov/seermedicare /overview/seermed-fact-sheet.pdf. Published December 2013. Accessed December 18, 2014.
22. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database.Med Care. 1993;31(8):732-748.
23. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
24. Ma X, Wang R, Long JB, et al. The cost implications of prostate cancer screening in the Medicare population. Cancer. 2014;120(1):96-102.
25. National Cancer Institute. Surveillance, Epidemiology, and End Results program. http://seer.cancer.gov/about/factsheets/SEER-brochure.pdf. Published March 2012. Accessed December 18, 2014.
26. Simone JV, Hewitt M. Enhancing Data Systems to Improve the Quality of Cancer Care. Washington, DC: National Academies Press; 2000.
27. Centers for Medicare and Medicaid Services. Medicare enrollment and claim submission guidelines. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/MedicareClaimSubmissionGuidelines-ICN906764.pdf. Published August 2014. Accessed December 18, 2014.
28. Stryer DB, Weinick RM, Clancy CM. Reducing racial and ethnic disparities in health care. Health Serv Res. 2002;37(5):xv-xxvi.
29. Logan JL. Disparities in influenza immunization among US adults. J Natl Med Assoc. 2009;101(2):161-166.
30. Blewett LA, Johnson PJ, Lee B, Scal PB. When a usual source of care and usual provider matter: adult prevention and screening services. J Gen Intern Med. 2008;23(9):1354-1360.
31. Hoffman C, Paradise J. Health insurance and access to health care in the United States. AnnNY Acad Sci. 2008;1136:149-160.
32. Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. Milbank Q. 2005;83(3):457-502.
33. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data.Med Care. 1998;36(1):8-27.
34. National Cancer Institute. SEER training modules. http://training.seer.cancer.gov/melanoma/abstract-code-stage/staging.html. Accessed December 18, 2014.
35. DeMott K. Healthcare practices vary widely from town to town: regional Dartmouth Atlas. Health Syst Lead. 1997;4(1):2-3.
36. Health Resources and Services Administration. Area health resources files. http://ahrf.hrsa.gov/. Accessed December 18, 2014.
37. Ingram DD, Franco SJ. NCHS urban-rural classification scheme for counties. Vital Health Stat 2. 2012;(154):1-65.
38. Bouwmeester W, Twisk JW, Kappen TH, van Klei WA, Moons KG, Vergouwe Y. Prediction models for clustered data: comparison of a random intercept and standard regression model. BMC Med Res Methodol. 2013;13:19. doi:10.1186/1471-2288-13-19.
39. McLaughlin JM, Fisher JL, Paskett ED. Marital status and stage at diagnosis of cutaneous melanoma: results from the Surveillance Epidemiology and End Results (SEER) program, 1973-2006.Cancer. 2011;117(9):1984-1993.
40. Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. JAm Acad Dermatol. 2011;65(5)(suppl 1):S78-S86.
41. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol. 2011;65(5)(suppl 1):S17-25.e1-3. doi:10.1016/j.jaad.2011.04.032.
42. Richard MA, Grob JJ, Avril MF, et al. Delays in diagnosis and melanoma prognosis, II: the role of doctors. Int J Cancer. 2000;89(3):280-285.